Halozyme

Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8

... SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...s, and entering reservation code 57745069. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...4535) Diagnostics Index (HHD) Drop CR Bard, Inc. (NYSE: BCR ) IDEXX Laboratories (Nasdaq: IDXX ) Add Bruker Corporation (Nasdaq: BRKR ) halozyme Therapeutic (Nasdaq: HALO ) Emerging Cancer Index (HHJ) Drop Adventrx Pharmaceuticals, Inc. (Amex: ANX ) Keryx Biopharmaceuticals, Inc. (Nasd...

Halozyme Therapeutics Added to Nasdaq Biotech Index

... SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...ty criteria, visit http://www.nasdaq.com . About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Baxter Reports Strong Third Quarter Sales and Earnings

...EKA Research & Development Corp. and HHD, LLC, and halozyme Therapeutics, Inc. In addition, the company's resu...uring the period, including: -- An agreement with halozyme Therapeutics, Inc. to apply Halozyme's proprie... the company's in-licensing arrangement with halozyme Therapeutics, Inc. The after- tax impact of...

Halozyme in Medical Technology

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

... SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmac...," stated Jonathan Lim, M.D., President and CEO of halozyme Therapeutics. "The bisphosphonate program joins i...uPH20 to IV bisphosphonate alone. About halozyme Therapeutics, Inc. ...

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

... SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmac.... Under the terms of the agreement, Roche will pay halozyme for exclusive, global rights for the application o...logic target selected by Roche. "Roche and halozyme have successfully completed the necessary drug pro...

Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

...d - SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...or burden for a significant number of patients." halozyme is continuing its pharmacology, manufacturing and ...otherapeutic agents. Previous studies presented by halozyme (Thompson et al. Proceedings AACR Annual Meeting, ...

Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

...e for pivotal trials successfully determined - - halozyme to seek input from regulatory authorities in order...9 - SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...ent of Clinical Development and Medical Affairs at halozyme stated, "We are pleased the study demonstrated tha...

Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

... SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...dispersion and absorption of other injected drugs. halozyme plans to conduct additional clinical trials in its...zyme's website (http://www.halozyme.com ) About halozyme Therapeutics, Inc. ...

Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

... - SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...arily degrading hyaluronan under the skin. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

... - SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...velopment strategy for this new compound." About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... was the result of an agreement between Baxter and halozyme Therapeutics, Inc., under which Halozyme's proprie... meaningful difference in patients' lives. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex

...ty - SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...nt. As previously reported (see February 8, 2006 halozyme press release), the INcreased Flow Utilizing Subcu...s a trademark of Baxter International Inc. About halozyme Therapeutics, Inc. ...

Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer

... SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace... drugs instilled directly into the bladder. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Halozyme in Biological Technology

Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology

Development of New Route to Administer GAMMAGARD LIQUID(TM) 10% Could Make Home Therapy More Accessible; Collaboration Valued at Up to $47 Million DEERFIELD, Ill. and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX ) and Halozyme Therapeutics, Inc. (Nasdaq:...

Halozyme Receives $5.5 Million Payment From Baxter

... SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmac...has been booked as deferred revenue. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

...wswire-FirstCall/ -- Baxter International Inc. and halozyme Therapeutics, Inc. (Nasdaq: HALO ) today announc... in their home setting. "Baxter's work with halozyme represents a commitment to innovation and, in part...that advance patient care worldwide. About halozyme Therapeutics, Inc. ...

Halozyme Therapeutics Reports 2008 Third Quarter Financial Results

... SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace... ended September 30, 2008. "The fundamentals for halozyme have never been stronger and I am pleased with the...n Lim, M.D., President and CEO of Halozyme. "Other halozyme clinical programs are also moving forward expediti...

Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients

... SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace... before the end of the year and I congratulate the halozyme team for its outstanding performance." This expl... Summary of Results Reported for Phase 1 Study halozyme conducted a Phase 1 euglycemic clamp study in 26 v...

Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results

... SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...or 706-645-9291 for international callers. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Halozyme Therapeutics to Present at Upcoming Investor Conferences

... SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace... 30 days following the presentation dates. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...

Halozyme Therapeutics to Host Research Day for Investors and Analysts

... SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...tle, Vice President and Chief Commercial Officer halozyme will conduct a live webcast of the presentations b...ortly after the conclusion of the meeting. About halozyme Therapeutics, Inc. ...

Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development

... SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...Dr. Muchmore's high caliber and achievement to the halozyme leadership team. He is a widely respected endocrin...search, and corporate settings. Doug's addition to halozyme will immediately add value to the advancement of o...

Halozyme Therapeutics to Present at Upcoming Investor Conferences

... SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- halozyme Therapeutics, Inc. (Nasdaq: HALO ), a biopharmace...r 30 days following the presentation date. About halozyme Therapeutics, Inc. halozyme is a biopharmaceutical company developing and comm...